We are live on ! Find out more

Annovis Bio

ANVS

Market cap $37.2M

0.8644 USD

+0.0111

1.3%

At close Updated Nov 12, 1:01 PM EST

1 day

1.3%

5 days

23.49%

1 month

-24.83%

3 months

-51.98%

6 months

-62.09%

Year to date

-76.32%

1 year

-64.43%

5 years

-97.12%

10 years

-90.99%

About: Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Employees: 7

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 8.3%

Neutral 83.3%

Negative 8.3%

Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap

U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection through 2044 Form B is used in the Company's ongoing pivotal Phase 3 trial in early Alzheimer's disease and in the open-label extension Parkinson's study Issued patent strengthens the Company's intellectual property position ahead of the top-line data readout from its fully enrolled pivotal Phase 3 Alzheimer's trial MALVERN, Pa.

Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap

Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman

Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash to fund operations through the pivotal Phase 3 Alzheimer's data readout in March 2027 MALVERN, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that its Chairman participated in the underwritten public offering and contributed $5.00 million, or approximately 24% of the $21.0 million offering, which closed on November 6, 2026.

Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman

Annovis Announces Pricing of $21.0 Million Public Offering

MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of (i) 19,000,000 shares of its common stock and, in lieu of common stock to certain investors that so chose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,000,000 shares of its common stock, and (ii) accompanying warrants to purchase up to 21,000,000 shares of common stock.

Annovis Announces Pricing of $21.0 Million Public Offering

Annovis Announces Launch of Proposed Public Offering

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock (or pre-funded warrants in lieu thereof) and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the securities in the proposed offering will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Annovis Announces Launch of Proposed Public Offering

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on October 29, 2026, it received notice (the “Notice”) from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholders' equity was less than $50 million.

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that Maria Maccecchini, PhD, Founder, President and CEO of Annovis, will participate and present in two industry events in November.

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

Annovis to Attend the CTAD 2026 with Three Presentations

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will attend and present at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, happening November 16-19 in Boston, MA.

Annovis to Attend the CTAD 2026 with Three Presentations

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease

MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease

Zacks Investment Research

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio (ANVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA

Annovis Bio NYSE: ANVS said it expects to report top-line results from the six-month portion of its pivotal Phase III Alzheimer's disease trial in March 2027, while preparing a rolling new drug application, or NDA, that management said could begin in May if the study meets its efficacy requirements.

Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA

See News Rankings

Price charts implemented using Lightweight Charts™